CHARLOTTE, N.C.--(BUSINESS WIRE)-- Premier Inc. (NASDAQ: PINC), through its ProvideGx™ program, has partnered with Pfizer Inc. to supply Corvert® (ibutilide fumarate injection) and Vincristine Sulfate ...
InCarda Therapeutics has reported phase 2 trial data on its inhaled challenger to Pfizer’s intravenous anti-arrhythmic drug Corvert. The readout sets InCarda up to start a single pivotal trial in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results